Featured Research

from universities, journals, and other organizations

Promising Indiana University Lung Cancer Trial Enters New Phase

Date:
January 15, 2002
Source:
Indiana University
Summary:
The Indiana University School of Medicine is now recruiting patients for the second phase of a lung cancer trial that has shown promising results. The procedure, extracranial stereotactic radioablation, uses three-dimensional imaging and high doses of radiation to more precisely target and kill cancer cells in the lung. It uses treatment concepts similar to those used in Gamma Knife radiosurgery, a non-invasive technique shown to be effective in treating brain tumors.

The Indiana University School of Medicine is now recruiting patients for the second phase of a lung cancer trial that has shown promising results.

Related Articles


The procedure, extracranial stereotactic radioablation, uses three-dimensional imaging and high doses of radiation to more precisely target and kill cancer cells in the lung. It uses treatment concepts similar to those used in Gamma Knife radiosurgery, a non-invasive technique shown to be effective in treating brain tumors.

The procedure uses a 3-D computer generated grid system to more precisely map the location where therapy is directed. The patient is positioned in a specially fitted, lightweight body frame that limits mobility to ensure the precision of photon beams aimed at the tumor. "One advantage of the combined technology is that the risk of damaging healthy tissue despite such potent doses of radiation is reduced in comparison to conventional radiation."

"The results of the first phase were very encouraging and somewhat surprising," says Robert D. Timmerman, M.D., assistant professor of radiation oncology and the trial's principal investigator at the Indiana University Cancer Center. "We thought patients only would be able to tolerate lower doses since frail patients typically can't tolerate such rigorous treatment. To our surprise, we were able to increase dose levels without prohibitive toxicity."

This latest phase seeks to enroll 35 patients with early stage, non-small cell lung cancer whose tumors have not spread to lymph nodes or beyond and who have health conditions such as emphysema, severe heart disease, diabetes or a history of strokes, therefore making them poor candidates for surgery.

"Using a potent dose with assurance of reasonable safety to patients, we now want to measure the rate of controlling lung cancer and measure the patient's overall disease-free survival," Dr. Timmerman says.

Early stage lung cancer traditionally is treated with surgery, conventional radiation, or both. There is a 60 percent to 70 percent cure rate for early stage lung cancer in patients undergoing surgery, and a 20 percent to 30 percent cure rate for those treated with conventional radiation, which usually involves up to six weeks of daily radiation treatments.

In contrast, Phase 2 of this IU lung cancer trial delivers the entire treatment in three visits.

"We're optimistic this new therapy will bridge this large disparity giving patients a better chance of survival and a cure," notes Dr. Timmerman.


Story Source:

The above story is based on materials provided by Indiana University. Note: Materials may be edited for content and length.


Cite This Page:

Indiana University. "Promising Indiana University Lung Cancer Trial Enters New Phase." ScienceDaily. ScienceDaily, 15 January 2002. <www.sciencedaily.com/releases/2002/01/020115074910.htm>.
Indiana University. (2002, January 15). Promising Indiana University Lung Cancer Trial Enters New Phase. ScienceDaily. Retrieved March 28, 2015 from www.sciencedaily.com/releases/2002/01/020115074910.htm
Indiana University. "Promising Indiana University Lung Cancer Trial Enters New Phase." ScienceDaily. www.sciencedaily.com/releases/2002/01/020115074910.htm (accessed March 28, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, March 28, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) — In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com
What's Different About This Latest Ebola Vaccine

What's Different About This Latest Ebola Vaccine

Newsy (Mar. 26, 2015) — A whole virus Ebola vaccine has been shown to protect monkeys exposed to the virus. Here&apos;s what&apos;s different about this vaccine. Video provided by Newsy
Powered by NewsLook.com
HIV Outbreak Prompts Public Health Emergency In Indiana

HIV Outbreak Prompts Public Health Emergency In Indiana

Newsy (Mar. 26, 2015) — Indiana Gov. Mike Pence says he will bring additional state resources to help stop the epidemic. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins